What guidance did RxSight's management provide for the next earnings period?

What does RxSight do and what are its main business segments?

What were the key takeaways from RxSight’s earnings call?

Did RxSight beat or miss consensus estimates last quarter?

What is the market's earnings forecast for RxSight next quarter?

What is RxSight's latest dividend and current dividend yield?

What factors drove the changes in RxSight's revenue and profit?

What were the key takeaways from RxSight's earnings call?

- **Revenue decline**: Q4 2025 sales down 19% YoY to $32.6M, driven by LDD decline. LAL sales grew 12% to $28.2M, accounting for 86% of revenue.
- **Gross margin improvement**: 77.5% (vs. 71.6% YoY) due to higher LAL mix. 2026 gross margin guided to 70-72% due to inventory costs.
- **Installed base growth**: 1,134 LDDs (+17% YoY). LAL utilization improved sequentially, with 10% U.S. premium market penetration.
- **2026 guidance**: Revenue $120M-$135M (-5% midpoint). Q1 2026 expected to be weakest due to tough comps, with sequential improvement in Q2+.
- **International expansion**: Early-stage efforts in Europe, Asia, and Australia. Japan and China approvals pending.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $32.6 million (-19% YoY), driven by 48% decline in LDD sales ($11M vs. $3M). LAL sales grew 12% YoY to $28.2M, accounting for 86% of total revenue.
- Gross margin improved to 77.5% (vs. 71.6% YoY) due to higher LAL mix. Net loss: $9.2M ($0.22/share), adjusted loss: $1.3M ($0.03/share).
- 2026 guidance: Revenue $120M-$135M (-5% midpoint), gross margin 70%-72%, operating expenses $150M-$160M. Challenges include higher-cost inventory and seasonal Q1 weakness.

**【CEO Strategic Remarks】**
- Installed base growth: 1,134 LDDs (+17% YoY). LAL utilization improved sequentially, with 10% U.S. premium market penetration by volume.
- Innovation pipeline: Over 20 FDA approvals since 2021, including ActivShield and LAL+. International expansion focused on Europe, Asia, and Australia, with approvals in EU, South Korea, Singapore, and Australia.
- Clinical validation: 93% of LALs achieve ±0.5D accuracy, per Q4 2025 study. 20,000+ eye registry data shows superior refractive outcomes vs. toric IOLs.

**【Q&A Highlights】**
- **2026 Outlook**: Q1 2026 sales expected to be lowest due to tough 2025 comps. Sequential improvement anticipated in Q2+ as higher-cost inventory is sold. LAL unit growth ~low single-digit YoY.
- **Gross Margin**: 70-72% guidance reflects transient manufacturing headwinds. Long-term 75%+ achievable with LAL mix expansion and international scale.
- **LDD Placements**: 2026 LDD sales to grow from Q4 2025 rate of 25/quarter, with OUS placements contributing later in the year.
- **Competition**: 2025 saw unusual intensity from competitors launching new multifocals. 2026 expected to normalize, with RxSight's adjustability differentiation intact.
- **International Strategy**: Focus on building KOL networks and clinical data in key markets. Japan and China approvals under review, with updates expected in 2026H2.

RxSight, Inc.(RXST)-20260226-2025 Q4 Earnings call transcript

- **Revenue Resilience**: Q3 2025 LAL revenue grew 6% YoY to $25.7M, despite overall revenue decline. LAL mix hit 85% of total revenue.
- **Gross Margin Breakthrough**: 79.9% gross margin (vs. 71.4% YoY), driven by cost efficiencies and strategic LDD sales.
- **Strategic Shift**: Transitioning from LDD sales to optimizing existing 1,109 LDD installed base, with focus on LAL procedure growth.
- **International Momentum**: EVP of International appointed to accelerate rollouts in priority markets, with early KOL engagement.
- **2026 Outlook**: Sequential LAL growth expected, with disciplined expense management and ~77% gross margin target.

**【CEO Summary Section】**
- **Commercial Execution Progress**: Q3 saw 2,000 U.S. surgeons implanting LAL, representing ~20% of total U.S. cataract surgeons. The company launched new programs (Masterclass, Elevate) to optimize LAL workflows and clinical confidence.
- **Installed Base Growth**: 1,109 LDDs in field (25% YoY increase), with focus on strategic expansion of LDDs and implanting surgeons.
- **International Expansion**: Added EVP of International to lead rollouts in Asia and Europe, with regulatory and commercial initiatives underway.
- **R&D Focus**: Simplifying workflows and broadening patient eligibility for adjustable vision correction.

**【CFO Financial Commentary】**
- **Revenue**: Q3 2025: $30.3M (-14% YoY, -10% QoQ). LAL revenue $25.7M (85% of total, +6% YoY). LDD sales $3.2M (-69% YoY, -38% QoQ).
- **Gross Margin**: 79.9% (844bps YoY improvement), driven by higher LAL mix and lower unit costs.
- **Operating Expenses**: SG&A $27.3M (+7% YoY, -6% QoQ). R&D $9.1M (+3% YoY, -11% QoQ).
- **Updated Guidance**: Full-year 2025 revenue $125M-$130M (narrowed from $120M-$130M). Gross margin 76%-77% (vs. prior 72%-74%). Operating expenses $145M-$155M.

**【Q&A Key Highlights】**
- **Metrics Focus**: CEO emphasized LAL procedures as leading indicator, with ~1.7-2 active surgeons per LDD. CFO noted LAL mix at 85% in Q3, targeting similar levels.
- **Competitive Landscape**: Lower Medicare reimbursement for standard cataract surgery (~11% 2026 decline) expected to drive premium IOL adoption. RxSight sees modest long-term impact from new entrants.
- **International Outlook**: Early-stage progress in Europe/Asia, with focus on KOL relationships and clinical data. 2026+ contributions expected as procedural volumes grow.
- **2026 Strategy**: Sequential LAL growth expected, with measured LDD placements focused on high-volume practices. Gross margin ~77% seen as sustainable baseline.


RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript

- **LAL Growth Despite Overall Decline**: Q2 LAL revenue up 13% YoY, 80% of total, offsetting LDD sales drop.
- **Customer Success Strategy**: Unified teams and expanded support aim to boost utilization and retention.
- **International Expansion**: Regulatory approvals in key markets set stage for future growth, though timelines cautious.
- **Financial Caution**: Full year guidance reflects slower second half, with focus on cost management and gross margin stability.
- **Cash Flow Concerns**: Breakeven dependent on revenue recovery, with challenges in LDD sales persisting.

**【CEO Summary Section】**
- **Addressing Sales Decline**: Focused on improving LAL adoption and utilization through a unified customer success organization, integrating 200 field employees to enhance support and training.
- **Customer Success Strategy**: Emphasized standardized frameworks for onboarding and long-term growth, leveraging peer-to-peer programs and new educational resources.
- **International Expansion**: Targeting Europe and Asia with regulatory approvals in South Korea and Singapore, aiming for modest revenue contributions in 2026-2027.
- **Innovation Investment**: Advancing R&D for postoperative workflow refinement and next-generation platform capabilities to expand patient accessibility.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Revenue $33.6M (-4% YoY, -11% QoQ), with LAL revenue at 80% of total, up from 68% YoY. LDD sales down 49% YoY.
- **Gross Margin**: 74.9%, driven by higher LAL mix. GAAP net loss $11.8M, non-GAAP loss $3.2M.
- **Expense Trends**: SG&A and R&D up 19% and 23% YoY due to personnel and stock-based compensation.
- **Full Year Guidance**: Revenue $120-130M, gross margin 72-74%, operating expenses $145-155M, reflecting cautious outlook.

**【Q&A Key Highlights】**
- **Q3 Outlook**: Guidance mid-range of $120-130M, with potential for LAL seasonality in Q4. LDD sales expected to remain soft.
- **Market vs. Company Performance**: Confidence in long-term premium IOL market growth, focusing on existing installed base utilization.
- **Cash Flow Breakeven**: Dependent on revenue recovery, with historical high gross margins supporting future breakeven potential.
- **International Timelines**: Regulatory approvals in Japan and China ongoing, with South Korea and Singapore showing early momentum.

RxSight, Inc. (RXST) Q2 2025 Earnings Call Transcript

- **Q1 Results**: $37.9M revenue (-6% QoQ) driven by macroeconomic headwinds; LAL sales growth (+37% YoY) offset by procedure volume decline.
- **Gross Margin Boost**: 74.8% gross margin vs. 70.1% YoY, enabled by cost efficiencies and LAL+ mix shift.
- **Innovation Edge**: Software update with spheric aberration correction and LDD monitoring features; EU/UK regulatory approvals.
- **Guidance Confidence**: Full-year $160-175M target reflects recovery in second half; 71%-73% gross margin maintained despite Q1 outperformance.
- **Competitive Resilience**: Differentiation via adjustable technology; anticipation of trial abatement in Q3.


**【CEO Opening Remarks】**
- Q1 2025 revenue of $37.9M (-6% QoQ, +28% YoY) marked first top-line miss since Q3 2021 due to macroeconomic headwinds and competitive disruptions.
- LALs sold: 27,579 (-5% QoQ, +37% YoY); LAL revenue: $27.2M (72% of total, +37% YoY).
- Key challenges: 75% of surveyed customers cited wealth effects reducing LAL procedure volumes; competitive trials eroded differentiation among multifocal IOLs.
- Offset by: 1,044 LDD installed base (+43% YoY); Q1 LDD revenue $9.4M (+8% YoY).
- Innovations: Software update with spheric aberration correction and LDD monitoring features; EU/UK regulatory approvals for LAL/LDD.

**【CFO Financial Highlights】**
- Gross margin: 74.8% (vs. 70.1% Q1 2024), driven by lower LAL costs and mix shift to higher-margin LAL+.
- OpEx: $28.6M (+23% YoY) due to personnel costs, registry data collection, and stock-based comp.
- R&D: $10.4M (+29% YoY) for clinical trials and software enhancements.
- Cash: $229.3M, supporting cash flow breakeven target.
- Full-year guidance: $160-175M revenue (+14%-25% YoY), 71%-73% gross margin, $150-160M OpEx.

**【Q&A Key Takeaways】**
- **Commercial Strategy**: Reinforced clinical education and marketing to address surgeon workload challenges; Q2 recovery expected in LAL volumes post-software upgrade.
- **International Expansion**: South Korea and UK approvals; targeting 10%+ premium IOL penetration in Europe/Asia.
- **Competitive Dynamics**: Anticipate trial abatement in Q3; LAL's customization advantage vs. commoditized multifocals.
- **Tariffs**: LAL/LDD exempt from US-China tariffs; all production sourced domestically.
- **LDD Treatment Centers**: Early-stage growth with potential to expand access; 3rd-party centers complementing traditional installs.


RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript

- **Q4 2024 Strong Growth**: Revenue up 41% YoY to $40.2 million, driven by 61% YoY LAL sales growth and 71.6% gross margin.
- **2025 Guidance**: $185-$197 million revenue (32%-41% YoY), 71%-73% gross margin, and $165-$170 million operating expenses.
- **LAL Utilization**: 10.9 LALs per LDD in Q4, with ~100,000 LALs implanted in 2024 (50% of U.S. premium IOL market growth).
- **Innovation Pipeline**: FDA-approved LAL+ extended diopter range and H2 2025 aspheric IOL functionality enhance customization.
- **Long-Term Vision**: Target 50%+ of U.S. premium IOL market, with global expansion beginning in 2026.


**【CEO Summary Section】**
- RxSight reported Q4 2024 revenue of $40.2 million, up 41% YoY, driven by strong LAL procedure volume and LDD installed base expansion. LAL sales reached 29,069 units, a 61% YoY increase, while LDD revenue was $10.7 million. Full-year 2024 revenue grew 57% to $139.9 million.
- Gross margin expanded to 71.6% in Q4 2024 (vs. 61.8% in Q4 2023) due to higher LAL revenue mix (71% vs. 62%) and cost efficiencies. Full-year gross margin was 70.7%.
- 2025 guidance: Revenue $185-$197 million (32%-41% YoY growth), gross margin 71%-73%, and operating expenses $165-$170 million. LAL utilization remains a key growth driver, with ~10% of U.S. premium IOL market penetration.
- Regulatory approvals for extended diopter ranges and aspheric IOL enhancements are expected to expand access and customization in 2025.

**【CFO Financial Commentary】**
- Q4 2024 net loss was $5.9 million ($0.15 per share), with adjusted net income of $1.3 million ($0.03 per share). Full-year 2024 net loss was $27.5 million ($0.71 per share), excluding $24.6 million in stock-based compensation.
- Cash balance ended at $237.2 million, with $107.5 million raised in a public offering during 2024. 2025 operating expenses are expected to increase 22%-25% YoY, driven by commercial team expansion (now ~200+ employees).
- LAL+ FDA approval for extended diopter ranges and aspheric IOL functionality (scheduled for H2 2025) will support clinical differentiation and adoption.

**【Q&A Key Highlights】**
- **LAL Utilization**: Q4 2024 LALs per LDD was 10.9, up from 8.7 in Q3. Cohorts of LDD installs consistently achieve ~10 LALs per LDD over time. 2024 LAL volume (~100,000) accounted for ~50% of U.S. premium IOL market growth.
- **2025 Seasonality**: Expect weaker Q1 and Q3, stronger Q2 and Q4. Non-U.S. revenue remains nominal in 2025, with meaningful impact anticipated in 2026+.
- **Competitive Landscape**: Adjustability is a unique differentiator, with ~75% of LAL cases converting from monofocal/toric IOLs. New LDD functionality (asphericity customization) opens door for higher-level patient customization.
- **R&D Allocation**: $40 million+ in 2025 for lens optics, LDD enhancements, and clinical data generation. Focus on incremental upgrades to existing platform (e.g., ActivShield, extended diopter ranges).
- **Gross Margin Outlook**: 71%-73% in 2025, with potential to exceed 80% at maturity as LAL becomes dominant revenue driver.


Actual	-3.24	-0.65	-0.47	-0.64	-0.61	-0.61	-0.56	-0.42	-0.4	-0.35	-0.26	-0.25	-0.16	-0.16	-0.15	-0.2	-0.29	-0.24	-0.22
Forecast	-0.6679	-0.6097	-0.6108	-0.5918	-0.6675	-0.714	-0.7493	-0.53	-0.4705	-0.4333	-0.3684	-0.2943	-0.2229	-0.2463	-0.1659	-0.2167	-0.2542	-0.3757	-0.3347
Surprise	-385.10%	-6.61%	+23.05%	-8.14%	+8.61%	+14.57%	+25.26%	+20.75%	+14.98%	+19.22%	+29.42%	+15.05%	+28.22%	+35.04%	+9.58%	+7.71%	-14.08%	+36.12%	+34.27%

RXST

RXST fundamentals

RXST Q4 2025 Earnings

Earnings Call

You can ask Aime

RXST

RXST fundamentals

RXST Q4 2025 Earnings

Earnings Call

RXST Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

RXST Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

RXST Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

RXST Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

RXST Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

You can ask Aime